menu
    • menu
    [{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"||SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Sequoia Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Stemirna Therapeutics \/ Sequoia Capital","highestDevelopmentStatusID":"5","companyTruncated":"Stemirna Therapeutics \/ Sequoia Capital"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Tibet Rhodiola Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Stemirna Therapeutics \/ Tibet Rhodiola Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Stemirna Therapeutics \/ Tibet Rhodiola Pharmaceutical"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stemirna Therapeutics \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"1","companyTruncated":"Stemirna Therapeutics \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SARS-Cov-2","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Stemirna Therapeutics

    Menu

    Stemirna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SW1115C3,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            China's Stemirna Halts mRNA Cancer Vaccine Trial, Researchers Say

                            Details : SW1115C3 is a personalized cancer vaccine (PCV) consisting of mRNA encoding a patient's tumor-specific neoantigens. It is being evaluated for the treatment of solid tumors.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 21, 2024

                            Lead Product(s) : SW1115C3,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neoantigen mRNA Personalised Cancer Vaccine,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 18, 2023

                            Lead Product(s) : Neoantigen mRNA Personalised Cancer Vaccine,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SWIM816,SARS-Cov-2

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 20, 2023

                            Lead Product(s) : SWIM816,SARS-Cov-2

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SW-BIC-213,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : SW-BIC-213,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SW-BIC-213,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Generation mRNA Booster Vaccine Against Emerging VOCs

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 14, 2022

                            Lead Product(s) : SW-BIC-213,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SW1115C3,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : SW1115C3,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 mRNA Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 03, 2021

                            Lead Product(s) : COVID-19 mRNA Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA COVID-19 Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Tibet Rhodiola Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stemirna COVID-19 Vaccine Candidate Obtains Clinical Trial Approval in China

                            Details : The potential vaccine, which Stemirna has started working on since January last year, is based on messenger RNA (mRNA) technology, Tibet Rhodiola Pharma, which is jointly developing the candidate with Stemirna.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 01, 2021

                            Lead Product(s) : mRNA COVID-19 Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Tibet Rhodiola Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA COVID-19 Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Sequoia Capital

                            Deal Size : $200.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            China's Stemirna Raises About $200 Mln to Fund Covid-19 Vaccine Development

                            Details : Stemirna Therapeutics raised nearly $200 million to speed up the clinical study of its COVID-19 vaccine candidate, SW-0123. It is in phase I study in China and preclinical data have been published in Nature.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 06, 2021

                            Lead Product(s) : mRNA COVID-19 Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Sequoia Capital

                            Deal Size : $200.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            Stemirna Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot testing of potential COVID-19 vaccine progresses

                            Details : The pilot testing of the vaccine for novel coronavirus, will be focused on animal toxicology and the vaccine's effectiveness. Clinical trials are expected to start in mid-April.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 17, 2020

                            Lead Product(s) : COVID-19 Vaccine,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth